Our top pick for
John Wiley & Sons Inc is a publishing - books business based in the US. John Wiley-and-Sons shares (JWA) are listed on the NYSE and all prices are listed in US Dollars. John Wiley-and-Sons employs 6,900 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$29.59 - $62.64|
|50-day moving average||$0.50|
|200-day moving average||$0.50|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.58|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing John Wiley-and-Sons stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of John Wiley-and-Sons's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
John Wiley-and-Sons's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, John Wiley-and-Sons shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
John Wiley-and-Sons's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $299.2 million.
The EBITDA is a measure of a John Wiley-and-Sons's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.8 billion|
|Operating margin TTM||11.35%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||4.22%|
|Return on equity TTM||-5.85%|
|Market capitalisation||$1.8 billion|
TTM: trailing 12 months
Dividend payout ratio: 52.3% of net profits
Recently John Wiley-and-Sons has paid out, on average, around 52.3% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), John Wiley-and-Sons shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In John Wiley-and-Sons's case, that would currently equate to about $N/A per share.
John Wiley-and-Sons's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
John Wiley-and-Sons's most recent dividend payout was on 20 October 2020.
Over the last 12 months, John Wiley-and-Sons's shares have ranged in value from as little as $29.5916 up to $62.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while John Wiley-and-Sons's is 0.701. This would suggest that John Wiley-and-Sons's shares are less volatile than average (for this exchange).
John Wiley & Sons, Inc. operates as a research and learning company worldwide. The company operates through three segments: Research Publishing & Platforms, Academic & Professional Learning, and Education Services. The Research Publishing & Platforms segment offers scientific, technical, medical, and scholarly journals, as well as related content and services to learned societies, individual researchers, other professionals, and academic, corporate, and government libraries. This segment also publishes physical sciences and engineering, health sciences, social sciences, and humanities and life sciences journals; and provides a publishing software and service for scholarly and professional societies, and publishers to deliver, host, enhance, market, and manage their content on the Web through the Literatum platform. It sells its products in digital and print formats through research libraries and library consortia, and independent subscription agents, as well as directly to professional society members, bookstores, online booksellers, and other customers. The Academic & Professional Learning segment provides scientific, professional, and education books in print and digital formats, digital courseware, and test preparation services to libraries, corporations, students, professionals, and researchers, as well as learning, development, and assessment services for businesses and professionals.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.